Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.78 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| [3H]-Zm-241385 SCHEMBL29443965 | 0.93 | ADORA2A (0.87) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 | |
| SCHEMBL23928202 | 0.92 | ADORA2A (0.85) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 | |
| SCHEMBL9326818 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 | |
| SCHEMBL1754980 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 | |
| SCHEMBL9327254 | 0.90 | ADORA2A (0.81) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 | |
| SCHEMBL26964863 | 0.90 | ADORA2A (0.81) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 | |
| SCHEMBL25030823 | 0.89 | ADORA2A (0.80) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 | |
| SCHEMBL23291213 | 0.89 | ADORA2A (0.83) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 | |
| SCHEMBL9328197 | 0.89 | ADORA2A (0.80) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 | |
| SCHEMBL23291132 | 0.89 | ADORA2A (0.83) | ADORA2AADORA2BADORA3ADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 961 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744659-A1 | ANTIBODY DERIVATIVE AND USE THEREOF | Tsinghua University (CN) | 2026-05-20 | — | — | EP | claimed |
| US-20260028675-A1 | PRECISION MEDICINE FOR PAIN: DIAGNOSTIC BIOMARKERS, PHARMACOGENOMICS, AND REPURPOSED DRUGS | UNIV INDIANA RES & TECH CORP (US) | 2026-01-29 | — | — | US | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | NOVARTIS AG (CH) | 2025-07-03 | — | — | US | claimed |
| US-12303618-B2 | Oxygen-generating cryogels | NORTHEASTERN UNIVERSITY (US) | 2025-05-20 | — | — | US | claimed |
| WO-2025011590-A1 | ANTIBODY DERIVATIVE AND USE THEREOF | 清华大学 | 2025-01-16 | — | — | WO | claimed |
| CN-119139469-A | Application of adenosine receptor inhibitor in preparing medicament for treating hyperlipidemia and cardiovascular and cerebrovascular diseases | 武汉大学 | 2024-12-17 | — | — | CN | claimed |
| US-20240219394-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-07-04 | — | — | US | claimed |
| EP-4382612-A1 | METHOD FOR MEASURING RESPONSE OF OLFACTORY RECEPTOR TO SUBSTANCE | AJINOMOTO CO., INC. (JP) | 2024-06-12 | — | — | EP | claimed |
| EP-4378957-A2 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO PD-1 | Novartis AG (CH) | 2024-06-05 | — | — | EP | claimed |
| US-20140056922-A1 | METHODS FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2014-02-27 | — | — | US | claimed |
| US-8536306-B2 | Human A2A adenosine receptor crystals and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-17 | — | — | US | claimed |
| US-20120093856-A1 | METHODS FOR USING EXTRACELLULAR ADENOSINE INHIBITORS AND ADENOSINE RECEPTOR INHIBITORS TO ENHANCE IMMUNE RESPONSE AND INFLAMMATION | The Gov of the USA as represented by the Secretary of the Dept. of Health and Human Services | 2012-04-19 | — | — | US | claimed |
| EP-1272897-B1 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR TREATING AND PREVENTING HEPATIC FIBROSIS, CIRRHOSIS AND FATTY LIVER | UNIV NEW YORK (US) | 2008-05-07 | — | — | EP | claimed |
| WO-2004070000-A2 | HTLV-I-CELL BINDING AND INHIBITION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-08-19 | — | — | WO | claimed |
| US-6555545-B2 | Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents | NEW YORK UNIVERSITY | 2003-04-29 | — | — | US | claimed |
| EP-1300147-A1 | Purine compounds and adenosine A2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus | Eisai Co. Ltd (JP) | 2003-04-09 | — | — | EP | claimed |
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | NEW YORK UNIVERSITY | 2002-01-03 | — | — | US | claimed |
| US-5270311-A | [1,2,4]-Triazolo[1,5-a]and pyrazolo[2,3-a][1,3,5]triazine derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-14 | — | — | US | claimed |
| EP-0459702-A1 | Azole Derivatives | ZENECA LIMITED (GB) | 1991-12-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028675-A1 | PRECISION MEDICINE FOR PAIN: DIAGNOSTIC BIOMARKERS, PHARMACOGENOMICS, AND REPURPOSED DRUGS | MYLK3, MYL12A, MYLK2 | ADORA2A 4858/4885ADORA2B 4514/4885ADORA3 4482/4885 |
| US-20020002145-A1 | Adenosine A2A receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA3 4/4885 |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | ADORA2A 1416/4885ADORA2B 2208/4885ADORA3 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.